Abc Derm Cold Cream Visage  & Corps

Approved Indications:
Miscellaneous topical agents are used in the treatment, prevention, or symptomatic relief of various dermatologic, mucosal, or wound-related conditions. Common approved indications include:

• Minor to moderate burns – e.g., silver sulfadiazine 1% cream
• Localized skin infections – e.g., mupirocin ointment for impetigo
• Neuropathic pain – e.g., lidocaine 5% patch for postherpetic neuralgia
• Pruritus relief – e.g., pramoxine-based products
• Wound healing enhancement – e.g., becaplermin gel for diabetic foot ulcers
• Skin protection/barrier restoration – e.g., zinc oxide for diaper dermatitis, pressure sores
• Hyperkeratotic lesions – e.g., salicylic acid for warts, corns, psoriasis

Clinically Accepted Off-Label Uses:

• Radiation dermatitis prophylaxis and management
• Perianal discomfort or fissures
• Topical pain management in musculoskeletal conditions
• Adjunctive use in chronic eczema, seborrheic dermatitis, or psoriasis
• Pre-procedural anesthesia in dermatologic procedures

Adults:

• Silver sulfadiazine 1% cream: Apply a thin layer once or twice daily to cleaned burn area.
• Mupirocin 2% ointment: Apply 3 times daily for 5–10 days.
• Lidocaine 5% patch: Apply to intact skin for up to 12 hours within a 24-hour period.
• Pramoxine lotion/cream: Apply 3–4 times daily as needed.
• Zinc oxide ointment: Apply as needed to affected areas, typically 2–4 times daily.
• Salicylic acid (17% liquid or 40% patch): Apply to wart or corn once or twice daily, usually for 2–12 weeks.

Pediatrics:

• Use with caution depending on product:
• Zinc oxide and pramoxine: Safe in infants for diaper rash or itch.
• Mupirocin: Safe in children over 2 months.
• Lidocaine/prilocaine (EMLA): Use with caution in infants; contraindicated in neonates <3 months.

Geriatrics:

• Same as adult dosing; monitor for increased systemic absorption due to thinner skin or compromised skin barrier.

Renal/Hepatic Impairment:

• Silver-containing agents: Use cautiously in renal impairment.
• Lidocaine and prilocaine-based agents: Caution in hepatic dysfunction due to hepatic metabolism.

Route of Administration:

• Topical to intact or affected skin as indicated.

Duration of Use:

• Generally short-term (5–14 days), or as prescribed for chronic care (e.g., chronic wounds or dermatitis).

Miscellaneous topical agents exhibit diverse mechanisms depending on their pharmacologic class. Antibacterial agents like mupirocin inhibit bacterial protein synthesis by targeting isoleucyl-tRNA synthetase. Local anesthetics such as lidocaine block voltage-gated sodium channels, preventing nerve impulse propagation. Salicylic acid acts as a keratolytic by breaking down intercellular bonds in the stratum corneum. Zinc oxide serves as a physical barrier and mild antiseptic. Becaplermin, a recombinant platelet-derived growth factor, stimulates chemotaxis and proliferation of cells essential for wound healing. These agents function either locally to relieve symptoms or promote tissue repair without significant systemic activity.

Absorption:

• Varies by agent and condition of the skin.
• Minimal for zinc oxide, mupirocin (intact skin).
• Increased absorption for lidocaine or silver-based agents if applied to broken skin or large surface areas.

Distribution:

• Primarily localized at the application site.

Metabolism:

• Lidocaine undergoes hepatic metabolism via CYP1A2 and CYP3A4.
• Mupirocin is metabolized to inactive monic acid.

Half-life:

• Not clinically relevant for most topical agents due to local effects.
• Lidocaine: ~1.5–2 hours if absorbed.

Excretion:

• Lidocaine and metabolites are excreted renally.
• Silver is excreted slowly and may accumulate.

• Pregnancy:
• Most agents are Category B or C (older FDA system).
• Topical use of mupirocin, lidocaine, pramoxine, and zinc oxide is generally considered safe.
• Avoid silver sulfadiazine in late pregnancy due to potential kernicterus risk.
• Lactation:
• Safe when applied away from the nipple.
• Wash thoroughly before breastfeeding if applied near the breast.
• Lidocaine is minimally excreted in breast milk in small amounts and is considered compatible with breastfeeding.
• Caution is advised due to limited systemic data for some agents; use only when clearly indicated.

• Primary Therapeutic Class: Topical dermatologic agents
• Subclasses Include:
• Topical antimicrobials
• Local anesthetics
• Barrier/protective agents
• Keratolytics
• Wound healing agents
• Antipruritics
• Miscellaneous agents

• Hypersensitivity to the drug or any of its components
• Application to broken, infected, or oozing skin (for some anesthetic formulations)
• Use in neonates <3 months for lidocaine/prilocaine (risk of methemoglobinemia)
• Large surface area application (especially with lidocaine or silver products)
• Concurrent use of enzymatic wound debriders with silver-based creams

• Systemic toxicity risk if applied to large or compromised skin areas (e.g., lidocaine or silver agents)
• Methemoglobinemia risk with topical anesthetics in infants
• Delayed wound healing with prolonged silver agent use
• Photosensitivity with coal tar or salicylic acid products
• Contact dermatitis or allergic skin reactions possible
• Avoid eye and mucous membrane exposure unless indicated for mucosal use

Clinical Monitoring:

• Signs of local hypersensitivity
• Systemic toxicity in pediatric, elderly, or renally impaired patients
• Response of treated area (e.g., healing, infection resolution)

Common:

• Skin irritation (burning, redness, dryness)
• Local pruritus or rash
• Peeling or scaling (e.g., salicylic acid)

Less Common:

• Allergic contact dermatitis
• Delayed wound healing

Serious/Rare:

• Systemic lidocaine toxicity (CNS depression, arrhythmias)
• Methemoglobinemia (especially in infants with prilocaine/lidocaine creams)
• Argyria (long-term silver exposure)
• Anaphylaxis (rare)

Severity and Timing:

• Mild and self-limiting in most cases.
• Systemic effects typically occur only with prolonged or excessive application.

• Topical lidocaine + class I antiarrhythmics: Additive cardiotoxicity
• Silver sulfadiazine + enzymatic debriders: Inactivation of enzymatic action
• Systemic absorption of salicylates + anticoagulants (e.g., warfarin): Potential enhanced bleeding risk
• CYP450 Involvement:
• Lidocaine: CYP1A2, CYP3A4 metabolism
• Other agents: Minimal systemic metabolism
• Food or Alcohol: Not applicable for topical agents.

• 2023–2024 Clinical Updates:
• Silver-based products: Use discouraged in long-term wound care due to cytotoxicity and delayed healing.
• Mupirocin resistance: Minimize routine prophylactic use; reserve for confirmed bacterial skin infections.
• Topical anesthetics (EMLA): Enhanced pediatric dosing guidance to reduce methemoglobinemia risk.
• Wound care guidelines: Encourage evidence-based use of protectants and non-antibiotic topicals for pressure ulcers.

• Temperature: Store at 20°C to 25°C (68°F to 77°F); excursions between 15°C–30°C allowed
• Humidity: Protect from excess moisture
• Light: Keep away from direct light, especially silver-containing and lidocaine-based products
• Special Instructions:
• Lidocaine patches: Store flat in sealed pouch, avoid heat sources
• EMLA cream: Do not freeze
• Zinc oxide and salicylic acid: Store tightly closed, away from heat or flame
• No reconstitution required unless specifically directed by manufacturer